| Literature DB >> 29265639 |
Kim M Hare1, Susan J Pizzutto1, Anne B Chang1,2,3, Heidi C Smith-Vaughan1,4, Gabrielle B McCallum1, Jemima Beissbarth1, Lesley Versteegh1, Keith Grimwood4,5,6.
Abstract
BACKGROUND: Differentiating lower airway bacterial infection from possible upper airway contamination in children with endobronchial disorders undergoing bronchoalveolar lavage (BAL) is important for guiding management. A diagnostic bacterial load threshold based on inflammatory markers has been determined to differentiate infection from upper airway contamination in infants with cystic fibrosis, but not for children with protracted bacterial bronchitis (PBB), chronic suppurative lung disease (CSLD), or bronchiectasis.Entities:
Keywords: antibiotic therapy; bronchiectasis; chronic suppurative lung disease; diagnostic threshold; protracted bacterial bronchitis
Mesh:
Substances:
Year: 2017 PMID: 29265639 PMCID: PMC7167837 DOI: 10.1002/ppul.23931
Source DB: PubMed Journal: Pediatr Pulmonol ISSN: 1099-0496
Demographic, antibiotic use, pneumococcal conjugate vaccine status, and virus detection data by center and chronic endobronchial disorder
| NT | Qld | ||||||
|---|---|---|---|---|---|---|---|
| All children with chronic endobronchial disorders | CSLD | BE | PBB | CSLD | BE | Controls | |
| Number | 655 | 22 | 235 | 203 | 13 | 182 | 67 |
| Male | 382 (58%) | 12 (55%) | 130 (55%) | 130 (64%) | 6 (46%) | 104 (57%) | 45 (67%) |
| Median age in years (IQR) | 2.3 (1.5‐4.3) | 2.8 (1.5‐3.6) | 2.3 (1.6‐3.7) | 1.7 (1.1‐3.2) | 2.5 (1.8‐3.9) | 3.5 (2.1‐6.0) | 1.6 (0.7‐3.7) |
| Indigenous | 288/645 | 14 (64%) | 221 (94%) | 15/200 | 1 (7.7%) | 37/175 | 4 (6.0%) |
| Beta‐lactam antibiotics | 79/646 | 1 (4.6%) | 36/234 | 19/202 | 3 (23%) | 20/175 | 3 (4.5%) |
| Macrolide antibiotics | 160/646 | 12 (55%) | 122/234 | 8/202 | 2 (15%) | 16/175 | 1 (1.5%) |
| PCV vaccinated | 587/645 | 20 (91%) | 227 (97%) | 185/200 | 10 (77%) | 145/175 | 44/66 |
| Virus detected | 141/550 | 1/14 | 22/149 | 69/194 | 1 (7.7%) | 48/180 | 9/65 |
BE, bronchiectasis; CSLD, chronic suppurative lung disease; IQR, interquartile range; NT, Northern Territory; PBB, protracted bacterial bronchitis; PCV, pneumococcal conjugate vaccine; Qld, Queensland; RSV, respiratory syncytial virus.
10 Qld children had records missing for Indigenous status.
Recorded as current antibiotics (Qld) or taken in the 2‐week preceding bronchoscopy (NT) (eight Qld children and one NT child had missing antibiotic data).
≥2 doses of any PCV (11 Qld children had missing vaccination data).
Any of adenovirus, human metapneumovirus, influenza virus A/B, parainfluenza virus 1‐3, or RSV (13 Qld children had missing virus data, standard eight viruses tested for 163 NT children only).
Lower airway respiratory bacterial pathogen load in children with chronic endobronchial disorders
| Received macrolide antibiotics within previous 2 weeks | |||||
|---|---|---|---|---|---|
| Bacterial load (CFU/mL BAL) | Disease controls | All children with chronic endobronchial disorders | Yes | No | Difference ( |
| Negative | 34 (51%) | 170 (26%) | 54 (34%) | 116 (24%) |
|
| ≥102 and <103 | 1 (1.5%) | 53 (8%) | 24 (15%) | 29 (6%) | < |
| ≥103 and <104 | 1 (1.5%) | 45 (7%) | 19 (12%) | 25 (5%) |
|
| ≥104 and <105 | 11 (16%) | 79 (12%) | 24 (15%) | 55 (11%) | 0.217 |
| ≥105 | 20 (30%) | 308 (47%) | 39 (24%) | 261 (54%) | < |
| Total | 67 | 655 | 160 | 486 | |
BAL, bronchoalveolar lavage; CFU, colony‐forming units.
Any of H influenzae, S pneumoniae, M catarrhalis, S aureus, or P aeruginosa.
Two‐sample test of proportions for 646 children with chronic endobronchial disorders and available antibiotic use data who did or did not receive macrolide antibiotics; bold values, P < 0.05.
Lower airway cellularity in children with chronic endobronchial disorders
| Disease controls | All children with chronic endobronchial disorders | Received macrolide antibiotics within previous 2 weeks | Difference | ||
|---|---|---|---|---|---|
| Number | 67 | 655 | Yes ( | No ( |
|
| TCC | 123 (97, 155) | 292 (268, 319) | 308 (263, 361) | 288 (260, 319) | 0.629 |
| Neutrophils | 5 (3, 7) | 47 (40, 56) | 27 (19, 37) | 56 (47, 67) | < |
| Percent neutrophils | 4.0 (2.0, 8.0) | 20 (6.7, 55) | 8.3 (3.0, 32) | 24 (8.7, 59) | < |
|
| |||||
| High TCC | 6/66 (9%) | 206/612 (34%) | 48/140 (34%) | 156/463 (34%) | 0.897 |
| Neutrophilia | 5/65 (8%) | 336/613 (55%) | 50/143 (35%) | 281/461 (61%) | < |
BAL, bronchoalveolar lavage; CI, confidence interval; GM, geometric mean; IQR, interquartile range; TCC, total cell count.
Between 646 children with chronic endobronchial disorders and available antibiotic use data who did or did not receive macrolide antibiotics.
Two‐sample Wilcoxon rank‐sum (Mann‐Whitney) test; bold values, P < 0.05..
GM (95% CI) × 103 cells/mL.
Median (IQR).
Two‐sample test of proportions; bold values, P < 0.05..
TCC >400 × 103 cells/mL.
Airway neutrophils >15% BAL leukocytes.
Figure 1Paired airway cellularity and respiratory bacterial pathogen load data from 610 children with chronic endobronchial disorders, and 66 control children. CFU, colony‐forming units; Neu, neutrophils; TCC, total cell count. Error bars represent 95% confidence intervals. Pathogens included any of H influenzae, S pneumoniae, M catarrhalis, S aureus, or P aeruginosa
Factors associated with high total cell count or neutrophilia in the lower airways of children with chronic endobronchial disorders
| Univariate analyses | Multivariable analyses | |||
|---|---|---|---|---|
| Factor | High TCC | Neutrophilia | High TCC | Neutrophilia |
| Age (years) | 0.97 (0.92, 1.03) | 0.98 (0.93, 1.04) | na | na |
| Male | 0.90 (0.64, 1.27) | 0.92 (0.67, 1.27) | na | na |
| Indigenous |
|
|
| 0.75 (0.49, 1.13) |
| Beta‐lactamsd | 1.36 (0.83, 2.23) | 1.17 (0.71, 1.91) | na | na |
| Macrolides | 1.03 (0.69, 1.53) |
| na | 0.63 (0.38, 1.06) |
| Respiratory virus | 1.21 (0.80, 1.82) |
| na | 1.48 (0.94, 2.33) |
| Bacterial load (CFU/mL BAL) | No growth Reference | No growth Reference | ||
| ≥102 and <103 | ≥102 and <103 | |||
| 1.07 (0.52, 2.22) | 0.74 (0.38, 1.46) | 0.82 (0.39, 1.73) | 0.60 (0.26, 1.38) | |
| ≥103 and <104 | ≥103 and <104 | |||
| 1.11 (0.51, 2.42) | 1.09 (0.55, 2.19) | 0.93 (0.42, 2.06) | 1.07 (0.45, 2.57) | |
| ≥104 and <105 | ≥104 and <105 | |||
| 1.73 (0.95, 3.13) |
| 1.64 (0.89, 3.01) | 1.60 (0.85, 3.00) | |
| ≥105 | ≥105 | |||
|
|
|
|
| |
BAL, bronchoalveolar lavage; CFU, colony forming units; na, not applicable; NT, Northern Territory; Qld, Queensland; RSV, respiratory syncytial virus; TCC, total cell count.
Odds ratio (95% confidence interval); bold values, P < 0.05.
TCC >400 × 103 cells/mL (data available for 612/655 children).
Neutrophils >15% BAL leukocytes (data available for 613/655 children).
Recorded as current antibiotics (Qld) or taken <2‐week preceding bronchoscopy (NT) (data available for 646/655 children).
Any of adenovirus, human metapneumovirus, influenza virus A/B, parainfluenza virus 1‐3, or RSV (data available for 550/655 children).
Any of S pneumoniae, H influenzae, M catarrhalis, S aureus, or P aeruginosa.
Figure 2Paired airway cellularity and respiratory bacterial pathogen load data from 461 children with chronic endobronchial disorders, and 65 control children, who had not received macrolide antibiotics. Recorded as current antibiotics or taken <2‐weeks preceding bronchoscopy. CFU, colony‐forming units; Neu, neutrophils; TCC, total cell count. Error bars represent 95% confidence intervals. Pathogens included any of H influenzae, S pneumoniae, M catarrhalis, S aureus, or P aeruginosa